A drug composition for topical application in the form of a gel, comprising 0.05 to 5.0 wt.-% of a non-sedating antihistamine selected from the group consisting of Bepotastine thereof; 1.0- to 2.0 wt.-% of crosslinked polyacrylic acid polymers; 0 to 0.4 wt.-% of aminopolycarboxylic acid; 20 to 40 wt.-% of Prim...

The present invention provides .novel process for micronized dienogest (I).The present invention provides micronized dienogest (I) .Micronization of Dienogest enhanced its dissolution rate in multimedia compared to non micronized material.The results suggest that micronization technique for the preparation of rapidl...

The present disclosure generally relates to the field of pharmaceuticals. Specifically, it relates to pharmaceutical formulations and compositions for cardiovascular complications comprising aspirin and P2Y12 inhibitors.

SUSTAINED RELEASE FORMULATION OF REMOGLIFLOZIN ETABONATE The present invention relates to pharmaceutical formulations. Specifically, the present invention relates to sustained release formulation for oral delivery of Remogliflozin or its pharmaceutically acceptable salts. The present invention further relates to...

The present disclosure relates to pharmaceutical compositions and formulations comprising bempedoic acid, clopidogrel and aspirin and process of preparing the same. The pharmaceutical formulation comprises bempedoic acid, clopidogrel and aspirin in discrete units, wherein bempedoic acid and clopidogrel are in immedi...